AstraZeneca reports SUPERNOVA trial of sipavibart met COVID prevention endpoint

“Positive” high-level results from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis trial showed AstraZeneca’s sipavibart, formerly AZD3152, an investigational long-acting antibody, demonstrated a statistically significant reduction in the incidence of symptomatic COVID-19 compared to control in an immunocompromised patient population. The trial met both dual primary endpoints; the first one being the relative risk reduction of symptomatic COVID-19 caused by any SARS-CoV-2 variant and the second being the relative risk reduction of infections caused by SARS-CoV-2 variants not containing the F456L mutation. SUPERNOVA demonstrated the potential benefit of sipavibart in an evolving variant landscape in which COVID-19 cases captured over the course of the trial were caused by several different SARS-CoV-2 variants, the company announced.